Search - tctmd.com

Displaying 341 - 360 of 939

Sort: Relevancy | Date

JenaValve Trilogy Meets the Challenge of AR in Early Real-World Use

News Conference News EuroPCR 2022

JenaValve Trilogy Meets the Challenge of AR in Early Real-World Use

May 18, 2022

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

News Conference News EuroPCR 2022

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

May 17, 2022

EP’s Diversity Problem: Women, Minorities Remain Underrepresented

News Conference News HRS 2022

EP’s Diversity Problem: Women, Minorities Remain Underrepresented

May 06, 2022

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

News Conference News HRS 2022

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

May 05, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

Global STEMI Outcomes May Improve With Tracking, GHATI Hints

News Conference News ACC 2022

Global STEMI Outcomes May Improve With Tracking, GHATI Hints

April 11, 2022

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

News Conference News ACC 2022

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

April 11, 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

April 08, 2022

Large Smartwatch Study Confirms AF in Most Patients Who Seek Care: mAF-App II

News Conference News ACC 2022

Large Smartwatch Study Confirms AF in Most Patients Who Seek Care: mAF-App II

Yael L. Maxwell

April 07, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

FLAVOUR FFR as Good as IVUS for Intermediate Coronary Stenoses

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

News Conference News ACC 2022

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

Michael O'Riordan

April 04, 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

April 02, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

April 02, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.